One of the VEGFR-TKIs recommended for the treatment of mRCC is tivozanib, which is approved in Europe as first-line treatment for advanced RCC, and as second-line treatment in VEGFR and mTOR inhibitor-naïve patients with advanced RCC after disease progression following cytokine therapy [27]. This evidence concerns the gene MTOR and renal cell carcinoma.